Although HSPG2 expression in BC has not been examined in detail, a recent study investigated the expression of HSPG2 in human TNBC and the ability of anti-HSPG2 antibodies to specifically target and inhibit tumor growth in a mouse xenograft model [58], showing that HSPG2 is a promising therapeutic target in TNBC. This evidence concerns the gene HSPG2 and neoplasm.